Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin–activin–follistatin– <scp>IGF</scp> ‐1 axis: Results from an exploratory, randomized, placebo‐controlled, crossover study

Short-term liraglutide reduced total body mass and regional trunk and android fat while also improving glycaemia, with no measurable effects on lean or bone tissue. Selective effects on hormones were observed, though their biological plausibility and clinical relevance as compensatory changes maintaining nonfat mass require further investigation. These findings provide early insights into initial responses to liraglutide therapy. Longer studies should assess whether sustained treatment modifies total and lean mass as well as endocrine regulators of muscle preservation.